Form 4 for EDIT Editas Medicine, Inc.
Accepted 2024-09-06 00:00:00 ET · period of report 2024-09-04 · accession 0001650664-24-000103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-06 | 2024-09-04 | EDIT | O'Neill Gilmore Neil | CEO, Dir | S - Sale | $3.42 | -1,555 | 313.7K | -0.5% | -$5,318 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-04 | S | D | 1,555 | $3.42 | 313,724 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4503. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |